Investor Centre

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® .

The move addresses issues raised by the US Food and Drug Administration (FDA) in a complete response letter received in June 2019 and follows completion by Chiesi Group of a supplemental human factor study in the first quarter of 2020.

If Bronchitol is approved by the FDA, Pharmaxis will receive a US$10 million (A$15.5 million) milestone payment on the supply of Bronchitol for the US commercial launch and mid to high teen percentage royalties on in-market net sales.

Watch the interview here.

Gary Phillips, CEO of Australian biopharma company, Pharmaxis Ltd, discusses ensuring continuity of supply of its products throughout the crisis, the timeframe for trials of its unique anti-fibrotic treatment for a rare bone cancer, broader impacts for biopharma research and trials, the opportunity for the global industry and the potential for PXS respiratory products in the clinical aftermath of COVID -19.

Recorded 29 April 2020.

Listen to the podcast here.

Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips presented at the NWR Virtual Health Conference on Friday 1 May 2020. 

Investors may view a recording of the presentation at the NWR website:   https://us02web.zoom.us/webinar/register/WN_pdWZYlHJRFmjH01LYGc0NQ